SCHEMBL6684094

SCHEMBL6684094

CC(C)(C)OC(=O)c1c[nH]c2ccccc12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 2/20 0.69
CREBBP Q92793 1/20 0.69
PBRM1 Q86U86 1/20 0.60
GPR84 Q9NQS5 1/20 0.59
ALDH1A1 P00352 2/20 0.56
ATM Q13315 1/20 0.56
MAPK1 P28482 2/20 0.55
KMT2A Q03164 2/20 0.53
LMNA P02545 2/20 0.52
TP53 P04637 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
MAPT P10636 2/20 0.51
HTR3E A5X5Y0 2/20 0.51
HTR3B O95264 2/20 0.51
CHRNA1 P02708 2/20 0.51
CHRNG P07510 2/20 0.51
CHRNB1 P11230 2/20 0.51
CHRNB2 P17787 2/20 0.51
CHRNA3 P32297 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27851449 0.98 NR4A2 (0.67) NR4A2CREBBPPBRM1GPR84ALDH1A1
SCHEMBL1093530 0.81 NR4A2 (1.00) NR4A2CREBBPPBRM1GPR84ALDH1A1
SCHEMBL30031033 0.81 NR4A2 (1.00) NR4A2CREBBPPBRM1GPR84ALDH1A1
SCHEMBL5163293 0.81 LMNA (0.57) NR4A2CREBBPPBRM1GPR84KMT2A
SCHEMBL27664022 0.81 PBRM1 (0.51) NR4A2CREBBPPBRM1GPR84ALDH1A1
SCHEMBL6991795 0.80 NR4A2 (0.51) NR4A2CREBBPALDH1A1LMNANPSR1
SCHEMBL1696922 0.80 NR4A2 (0.51) NR4A2CREBBPMAPTHTR3EHTR3B
Hydrochloric Acid SCHEMBL28254334 0.80 NR4A2 (0.97) NR4A2CREBBPPBRM1GPR84ALDH1A1
SCHEMBL3995918 0.80 NR4A2 (0.55) NR4A2CREBBPPBRM1GPR84ALDH1A1
SCHEMBL10780508 0.80 NPC1 (0.57) NR4A2CREBBPPBRM1GPR84ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109715167-A Lipid-substituted amino 1, 2-and 1, 3-diol compounds as modulators of TLR2 dimerization 神经孔疗法股份有限公司 2019-05-03 CN claimed
CN-103570688-A 2,5-diaminomethylpyrazine compounds, drug compositions, preparation method and use thereof SHANGHAI INST MATERIA MEDICA 2014-02-12 CN claimed
CN-112239468-B Metal-free solvent-free synthesis of fused pyridine heterocycles and biomedical applications thereof 印多尔印度理工学院 2025-05-27 CN disclosed
EP-4265621-A1 PYRROLE DERIVATIVE, AND PREPARATION METHOD AND USE THEREFOR Shenzhen Sungening Bio-Medical Co., Ltd. (CN) 2023-10-25 EP disclosed
WO-2022237813-A1 COMPOUND HAVING ALK INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF 盛世泰科生物医药技术(苏州)有限公司 2022-11-17 WO disclosed
CN-114616224-A Novel tricyclic 5-HT2Antagonists 安娜玛有限公司 2022-06-10 CN disclosed
US-20220119378-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2022-04-21 US disclosed
US-20220119378-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2022-04-21 US disclosed
CN-114106185-A anti-HER 2 antibodies and immunoconjugates 基因泰克公司 2022-03-01 CN disclosed
CN-107001479-B anti-HER 2 antibodies and immunoconjugates 基因泰克公司 2021-09-28 CN disclosed
CN-109328059-B Selective inhibitors of clinically important mutants of EGFR tyrosine kinase CS制药技术有限公司 2021-08-17 CN disclosed
CN-1950374-A Tetraazabenzo[e]azulene derivatives and analogs thereof PFIZER (US) 2007-04-18 CN disclosed
CN-1914207-A Aza * -indoline derivatives as medicaments EXELIXIS INC (US) 2007-02-14 CN disclosed
CN-1894264-A Organophosphorous indazole derivatives and use thereof as protein kinase inhibitors AVENTIS PHARMA SA (FR) 2007-01-10 CN disclosed
WO-2004063336-A2 USES OF DEAZAPURINES FOR THE TREATMENT OF REPERFUSION INJURIES, OSTEOPOROSIS AND/OR BONE METASTASIS EISAI CO. LTD. (JP) 2004-07-29 WO disclosed
CN-1418216-A Novel 2,3,4, 5-tetrahydro-1H- [1,4] diaza * o [1, 7-a ] indole compounds UPJOHN CO (US) 2003-05-14 CN disclosed
CN-1370176-A Subsstituted heterocycle fused gamma-carbolines BRISTOL MYERS SQUIBB CO (US) 2002-09-18 CN disclosed
CN-1208413-A Gonadotropin releasing hormone antagonists MERCK & CO INC (US) 1999-02-17 CN disclosed
US-5760032-A GASTROINTESTINAL DISORDERS AND NERVOUS SYSTEM DISORDERS YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1998-06-02 US disclosed
EP-0776892-A1 THIENYLAZOLE COMPOUND AND THIENOTRIAZOLODIAZEPINE COMPOUND YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1997-06-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119378-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB NR4A2 2024/4885CREBBP 607/4885PBRM1 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.